MET and renal cell carcinoma: A recent phase III clinical study of cabozantinib—which inhibits AXL in addition to MET and VEGFR—in renal cell carcinoma (RCC) patients progressing after VEGFR inhibitor treatment, supports the hypothesis that AXL inhibition could target resistance to VEGFR inhibition [106].